Earlier this month, the members of the HIT-CF Europe consortium gathered in Lisbon for a general update of the whole project. The major outcomes of this meeting include the development of standard protocols to be used by all the involved laboratories and the definition of the project to be submitted to European Medicines Agency for the regulation of organoid assay.

HIT-CF Europe is a research project that aims to provide a better treatment for patients with Cystic Fibrosis that carry rare mutations. For more information, please visit https://www.hitcf.org/.